Listed in the December 27, 2023 extract; not in the current extract (September 22, 2026): Reclipsen 21 (02420813), Reclipsen 28 (02417464). Source: odb-formulary-ed43-extract-2023-12-27.xml; compared with odb-formulary-ed43-extract-2026-09-22.xml.
Private plan not entered. Private-plan coverage, and how it coordinates with public programs, is not determined here; the Ontario public-program lines on this page remain conditional on the entered details and the program rules.
Desogestrel & ethinyl estradiol
All strengths: General benefit; same patient cost rules
Shared coverage and patient cost rules
StatusGeneral benefit
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
Apri 21 · DIN 02317192 · 0.15 mg & 0.03 mg · tablets, 21-pack
General benefitMarketed · checked October 5, 2026
Write on scriptno code needed
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Apri 21 · DIN 02317192
Manufacturer: Barr Laboratories Inc.; listing date 2009-04-01
Health Canada: Marketed since 2015-05-28 · brand APRI 21 · ATC G03AA09 DESOGESTREL AND ESTROGEN · form Tablet · route Oral · ingredients DESOGESTREL 0.15 MG, ETHINYL ESTRADIOL 0.03 MG · company Teva canada limited · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product recordApri 21: Formulary list price $5.28 per unit (the source does not state the unit; exact figure $5.2773). What the ministry pays, not the patient.
Ministry pays: $5.2773 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02317192)
Source record
DIN 02317192: Apri 21
Raw flags: sec3=Y
Item: 683200094; group id 793; item number 1930; lccId None; manufacturer id BAR
Source form: Tab-21 Pk; strength: 0.15mg & 0.03mg
Recorded listing: General benefit
Source prices (unrounded): $5.2773; ministry $5.2773
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02317192
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=80270
Interchangeable products
Freya 21 · DIN 02396491 · $5.2773
Marvelon 21 · DIN 02042487 · $5.2773
Miley 21 · DIN 02556553 · $5.2773
Mirvala 21 · DIN 02410249 · $5.2773
Shortage status: resolved shortage (ended December 1, 2022); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02317192
Shortage record checked October 6, 2026
Freya 21 · DIN 02396491 · 0.15 mg & 0.03 mg · tablets, 21-pack
General benefitMarketed · checked October 5, 2026
Write on scriptno code needed
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Freya 21 · DIN 02396491
Manufacturer: Famy Care Ltd; listing date 2013-05-31
Health Canada: Marketed since 2026-09-17 · brand FREYA 21 · ATC G03AA09 DESOGESTREL AND ESTROGEN · form Tablet · route Oral · ingredients DESOGESTREL 0.15 MG, ETHINYL ESTRADIOL 0.03 MG · company Senador laboratories private limited · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product recordFreya 21: Formulary list price $5.28 per unit (the source does not state the unit; exact figure $5.2773). What the ministry pays, not the patient.
Ministry pays: $5.2773 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02396491)
Source record
DIN 02396491: Freya 21
Raw flags: sec3=Y
Item: 683200094; group id 793; item number 1930; lccId None; manufacturer id FAM
Source form: Tab-21 Pk; strength: 0.15mg & 0.03mg
Recorded listing: General benefit
Source prices (unrounded): $5.2773; ministry $5.2773
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02396491
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=88154
Interchangeable products
Apri 21 · DIN 02317192 · $5.2773
Marvelon 21 · DIN 02042487 · $5.2773
Miley 21 · DIN 02556553 · $5.2773
Mirvala 21 · DIN 02410249 · $5.2773
Shortage status: resolved shortage (ended October 24, 2022); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02396491
Shortage record checked October 6, 2026
Marvelon 21 · DIN 02042487 · 0.15 mg & 0.03 mg · tablets, 21-pack
General benefitMarketed · checked October 5, 2026
Write on scriptno code needed
Savings card: RxHelp ONE lists Marvelon (read 2026-09-10) — brand-name savings card, free; cannot be combined with another card on the same claim.
(rxhelp.ca ↗)1 brand, same coverage
Marvelon 21 · DIN 02042487
Manufacturer: Organon Canada Ltd./Ltee; listing date 1996-10-01
Health Canada: Marketed since 2022-05-19 · brand MARVELON 21 · ATC G03AA09 DESOGESTREL AND ESTROGEN · form Tablet · route Oral · ingredients DESOGESTREL 0.15 MG, ETHINYL ESTRADIOL 0.03 MG · company Organon canada inc. · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product recordMinistry pays: $5.2773 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02042487)
Source record
DIN 02042487: Marvelon 21
Raw flags: sec3=Y
Item: 683200094; group id 793; item number 1930; lccId None; manufacturer id ORG
Source form: Tab-21 Pk; strength: 0.15mg & 0.03mg
Recorded listing: General benefit
Source prices (unrounded): $22.1600; ministry $5.2773
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02042487
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=14354
Interchangeable products
Apri 21 · DIN 02317192 · $5.2773
Freya 21 · DIN 02396491 · $5.2773
Miley 21 · DIN 02556553 · $5.2773
Mirvala 21 · DIN 02410249 · $5.2773
Shortage status: resolved shortage (ended February 21, 2018); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02042487
Shortage record checked October 6, 2026
Miley 21 · DIN 02556553 · 0.15 mg & 0.03 mg · tablets, 21-pack
General benefitMarketed · checked October 5, 2026
Write on scriptno code needed
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Miley 21 · DIN 02556553
Manufacturer: Ambicare Pharmaceuticals Inc.; listing date 2025-10-31
Health Canada: Marketed since 2025-08-18 · brand MILEY 21 · ATC G03AA09 DESOGESTREL AND ESTROGEN · form Tablet · route Oral · ingredients DESOGESTREL 0.15 MG, ETHINYL ESTRADIOL 0.03 MG · company Ambicare pharmaceuticals inc. · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product recordMiley 21: Formulary list price $5.28 per unit (the source does not state the unit; exact figure $5.2773). What the ministry pays, not the patient.
Ministry pays: $5.2773 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02556553)
Source record
DIN 02556553: Miley 21
Raw flags: sec3=Y
Item: 683200094; group id 793; item number 1930; lccId None; manufacturer id AMB
Source form: Tab-21 Pk; strength: 0.15mg & 0.03mg
Recorded listing: General benefit
Source prices (unrounded): $5.2773; ministry $5.2773
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02556553
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=104524
Interchangeable products
Apri 21 · DIN 02317192 · $5.2773
Freya 21 · DIN 02396491 · $5.2773
Marvelon 21 · DIN 02042487 · $5.2773
Mirvala 21 · DIN 02410249 · $5.2773
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02556553
Shortage record checked October 6, 2026
Mirvala 21 · DIN 02410249 · 0.15 mg & 0.03 mg · tablets, 21-pack
General benefitMarketed · checked November 17, 2026
Write on scriptno code needed
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Mirvala 21 · DIN 02410249
Manufacturer: Apotex Inc.; listing date 2014-01-30
Health Canada: Marketed since 2014-01-07 · brand MIRVALA 21 · ATC G03AA09 DESOGESTREL AND ESTROGEN · form Tablet · route Oral · ingredients DESOGESTREL 0.1500 MG/TAB, ETHINYL ESTRADIOL 0.0300 MG/TAB · company Apotex inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product recordMirvala 21: Formulary list price $5.28 per unit (the source does not state the unit; exact figure $5.2773). What the ministry pays, not the patient.
Ministry pays: $5.2773 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02410249)
Source record
DIN 02410249: Mirvala 21
Raw flags: sec3=Y
Item: 683200094; group id 793; item number 1930; lccId None; manufacturer id APX
Source form: Tab-21 Pk; strength: 0.15mg & 0.03mg
Recorded listing: General benefit
Source prices (unrounded): $5.2773; ministry $5.2773
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02410249
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=89490
Interchangeable products
Apri 21 · DIN 02317192 · $5.2773
Freya 21 · DIN 02396491 · $5.2773
Marvelon 21 · DIN 02042487 · $5.2773
Miley 21 · DIN 02556553 · $5.2773
Shortage status: resolved shortage (ended April 2, 2026); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02410249
Shortage record checked October 6, 2026
Apri 28 · DIN 02317206 · 0.15 mg & 0.03 mg · tablets, 28-pack
General benefitMarketed · checked October 5, 2026
Write on scriptno code needed
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Apri 28 · DIN 02317206
Manufacturer: Barr Laboratories Inc.; listing date 2009-04-01
Health Canada: Marketed since 2015-05-28 · brand APRI 28 · ATC G03AA09 DESOGESTREL AND ESTROGEN · form Tablet · route Oral · ingredients ETHINYL ESTRADIOL 0.03 MG, DESOGESTREL 0.15 MG · company Teva canada limited · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product recordApri 28: Formulary list price $5.28 per unit (the source does not state the unit; exact figure $5.2780). What the ministry pays, not the patient.
Ministry pays: $5.2780 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02317206)
Source record
DIN 02317206: Apri 28
Raw flags: sec3=Y
Item: 683200093; group id 793; item number 1931; lccId None; manufacturer id BAR
Source form: Tab-28 Pk; strength: 0.15mg & 0.03mg
Recorded listing: General benefit
Source prices (unrounded): $5.2780; ministry $5.2780
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02317206
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=80272
Interchangeable products
Freya 28 · DIN 02396610 · $5.2780
Marvelon 28 · DIN 02042479 · $5.2780
Miley 28 · DIN 02556561 · $5.2780
Mirvala 28 · DIN 02410257 · $5.2780
Shortage status: shortage reported ended July 31, 2026 (report last updated July 31, 2026); confirm supply with the pharmacy; reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02317206
Shortage record checked October 6, 2026
Freya 28 · DIN 02396610 · 0.15 mg & 0.03 mg · tablets, 28-pack
General benefitMarketed · checked October 5, 2026
Write on scriptno code needed
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Freya 28 · DIN 02396610
Manufacturer: Famy Care Ltd; listing date 2013-05-31
Health Canada: Marketed since 2026-09-17 · brand FREYA 28 · ATC G03AA09 DESOGESTREL AND ESTROGEN · form Tablet · route Oral · ingredients ETHINYL ESTRADIOL 0.03 MG, DESOGESTREL 0.15 MG · company Senador laboratories private limited · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product recordFreya 28: Formulary list price $5.28 per unit (the source does not state the unit; exact figure $5.2780). What the ministry pays, not the patient.
Ministry pays: $5.2780 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02396610)
Source record
DIN 02396610: Freya 28
Raw flags: sec3=Y
Item: 683200093; group id 793; item number 1931; lccId None; manufacturer id FAM
Source form: Tab-28 Pk; strength: 0.15mg & 0.03mg
Recorded listing: General benefit
Source prices (unrounded): $5.2780; ministry $5.2780
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02396610
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=88165
Interchangeable products
Apri 28 · DIN 02317206 · $5.2780
Marvelon 28 · DIN 02042479 · $5.2780
Miley 28 · DIN 02556561 · $5.2780
Mirvala 28 · DIN 02410257 · $5.2780
Shortage status: resolved shortage (ended October 26, 2022); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02396610
Shortage record checked October 6, 2026
Marvelon 28 · DIN 02042479 · 0.15 mg & 0.03 mg · tablets, 28-pack
General benefitMarketed · checked October 5, 2026
Write on scriptno code needed
Savings card: RxHelp ONE lists Marvelon (read 2026-09-10) — brand-name savings card, free; cannot be combined with another card on the same claim.
(rxhelp.ca ↗)1 brand, same coverage
Marvelon 28 · DIN 02042479
Manufacturer: Organon Canada Ltd./Ltee; listing date 1996-10-01
Health Canada: Marketed since 2022-06-17 · brand MARVELON 28 · ATC G03AA09 DESOGESTREL AND ESTROGEN · form Tablet · route Oral · ingredients DESOGESTREL 0.15 MG, ETHINYL ESTRADIOL 0.03 MG · company Organon canada inc. · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product recordMinistry pays: $5.2780 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02042479)
Source record
DIN 02042479: Marvelon 28
Raw flags: sec3=Y
Item: 683200093; group id 793; item number 1931; lccId None; manufacturer id ORG
Source form: Tab-28 Pk; strength: 0.15mg & 0.03mg
Recorded listing: General benefit
Source prices (unrounded): $22.1600; ministry $5.2780
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02042479
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=14355
Interchangeable products
Apri 28 · DIN 02317206 · $5.2780
Freya 28 · DIN 02396610 · $5.2780
Miley 28 · DIN 02556561 · $5.2780
Mirvala 28 · DIN 02410257 · $5.2780
Shortage status: resolved shortage (ended June 28, 2021); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02042479
Shortage record checked October 6, 2026
Miley 28 · DIN 02556561 · 0.15 mg & 0.03 mg · tablets, 28-pack
General benefitMarketed · checked October 5, 2026
Write on scriptno code needed
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Miley 28 · DIN 02556561
Manufacturer: Ambicare Pharmaceuticals Inc.; listing date 2025-10-31
Health Canada: Marketed since 2025-08-18 · brand MILEY 28 · ATC G03AA09 DESOGESTREL AND ESTROGEN · form Tablet · route Oral · ingredients ETHINYL ESTRADIOL 0.03 MG, DESOGESTREL 0.15 MG · company Ambicare pharmaceuticals inc. · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product recordMiley 28: Formulary list price $5.28 per unit (the source does not state the unit; exact figure $5.2780). What the ministry pays, not the patient.
Ministry pays: $5.2780 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02556561)
Source record
DIN 02556561: Miley 28
Raw flags: sec3=Y
Item: 683200093; group id 793; item number 1931; lccId None; manufacturer id AMB
Source form: Tab-28 Pk; strength: 0.15mg & 0.03mg
Recorded listing: General benefit
Source prices (unrounded): $5.2780; ministry $5.2780
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02556561
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=104525
Interchangeable products
Apri 28 · DIN 02317206 · $5.2780
Freya 28 · DIN 02396610 · $5.2780
Marvelon 28 · DIN 02042479 · $5.2780
Mirvala 28 · DIN 02410257 · $5.2780
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02556561
Shortage record checked October 6, 2026
Mirvala 28 · DIN 02410257 · 0.15 mg & 0.03 mg · tablets, 28-pack
General benefitMarketed · checked November 17, 2026
Write on scriptno code needed
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Mirvala 28 · DIN 02410257
Manufacturer: Apotex Inc.; listing date 2014-01-30
Health Canada: Marketed since 2014-01-07 · brand MIRVALA 28 · ATC G03AA09 DESOGESTREL AND ESTROGEN · form Tablet · route Oral · ingredients DESOGESTREL 0.1500 MG/TAB, ETHINYL ESTRADIOL 0.0300 MG/TAB · company Apotex inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product recordMirvala 28: Formulary list price $5.28 per unit (the source does not state the unit; exact figure $5.2780). What the ministry pays, not the patient.
Ministry pays: $5.2780 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02410257)
Source record
DIN 02410257: Mirvala 28
Raw flags: sec3=Y
Item: 683200093; group id 793; item number 1931; lccId None; manufacturer id APX
Source form: Tab-28 Pk; strength: 0.15mg & 0.03mg
Recorded listing: General benefit
Source prices (unrounded): $5.2780; ministry $5.2780
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02410257
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=89491
Interchangeable products
Apri 28 · DIN 02317206 · $5.2780
Freya 28 · DIN 02396610 · $5.2780
Marvelon 28 · DIN 02042479 · $5.2780
Miley 28 · DIN 02556561 · $5.2780
Shortage status: resolved shortage (ended April 16, 2026); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02410257
Shortage record checked October 6, 2026
Linessa 21 · DIN 02272903 · 3 Phase · tablets, 21-pack
General benefitMarketed · checked October 5, 2026
Write on scriptno code needed
No interchangeable product listed in the Ontario extract
Linessa 21 · DIN 02272903
Manufacturer: Aspen Pharma Trading Limited; listing date 2012-12-21
Health Canada: Marketed since 2019-02-15 · brand LINESSA 21 · ATC G03AB05 DESOGESTREL AND ESTROGEN · form Tablet · route Oral · ingredients ETHINYL ESTRADIOL 0.025 MG, ETHINYL ESTRADIOL 0.025 MG, DESOGESTREL 0.15 MG, ETHINYL ESTRADIOL 0.025 MG, DESOGESTREL 0.125 MG, DESOGESTREL 0.1 MG · company Aspen pharmacare canada inc. · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product recordLinessa 21: Formulary list price $20.25 per unit (the source does not state the unit; exact figure $20.2500). What the ministry pays, not the patient.
Ministry pays: $20.2500 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02272903)
Source record
DIN 02272903: Linessa 21
Raw flags: sec3=Y
Item: 683200113; group id 793; item number 1932; lccId None; manufacturer id ASN
Source form: Tabs-21 Pk; strength: 3 Phase
Recorded listing: General benefit
Source prices (unrounded): $20.2500; ministry $20.2500
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02272903
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=75841
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02272903
Shortage record checked October 6, 2026
Linessa 28 · DIN 02257238 · 3 Phase · tablets, 28-pack
General benefitMarketed · checked October 5, 2026
Write on scriptno code needed
No interchangeable product listed in the Ontario extract
Linessa 28 · DIN 02257238
Manufacturer: Aspen Pharma Trading Limited; listing date 2012-12-21
Health Canada: Marketed since 2019-05-13 · brand LINESSA 28 · ATC G03AB05 DESOGESTREL AND ESTROGEN · form Tablet · route Oral · ingredients DESOGESTREL 0.1 MG, ETHINYL ESTRADIOL 0.025 MG, ETHINYL ESTRADIOL 0.025 MG, DESOGESTREL 0.125 MG, DESOGESTREL 0.15 MG, ETHINYL ESTRADIOL 0.025 MG · company Aspen pharmacare canada inc. · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product recordLinessa 28: Formulary list price $20.25 per unit (the source does not state the unit; exact figure $20.2500). What the ministry pays, not the patient.
Ministry pays: $20.2500 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02257238)
Source record
DIN 02257238: Linessa 28
Raw flags: sec3=Y
Item: 683200114; group id 793; item number 1933; lccId None; manufacturer id ASN
Source form: Tabs-28 Pk; strength: 3 Phase
Recorded listing: General benefit
Source prices (unrounded): $20.2500; ministry $20.2500
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02257238
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=74243
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02257238
Shortage record checked October 6, 2026
Other products in the same Health Canada class (G03A, G03AA, G03AB): coverage varies; not interchangeable
- Drospirenone + ethinyl estradiol (Yasmin 21): general benefit
- Ethinyl estradiol + levonorgestrel (Alesse 21): general benefit, not a benefit
- Ethinyl estradiol + norethindrone (Brevicon): general benefit
- Ethinyl estradiol + norethindrone (Minestrin 1/20): general benefit
- Ethinyl estradiol + norgestimate (Tri-Cyclen): general benefit, not a benefit
- Drospirenone (Slynd): general benefit
3 more in the class list below
Other drugs in the same formulary class (68:32 Progestogens and Oral Contraceptives) and how they are covered
Matched class: 68:32 Progestogens and Oral Contraceptives
Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment.
Covered without a code on the Ontario formulary: DROSPIRENONE, DROSPIRENONE & ETHINYL ESTRADIOL, ETHINYL ESTRADIOL & NORETHINDRONE, ETHINYL ESTRADIOL & NORETHINDRONE ACETATE, LEVONORGESTREL
Some products covered without a code (check the product listing): ETHINYL ESTRADIOL & LEVONORGESTREL, MEDROXYPROGESTERONE ACETATE, NORETHINDRONE, NORGESTIMATE & ETHINYL ESTRADIOL
68:32 Progestogens and Oral Contraceptives
· 9 products · General benefit · strengths: 3.0mg & 0.03mg, 3.0mg & 0.02mg · Tab-21 Pk, Tab-28 Pk
· 20 products · General benefit (18), Off-Formulary Interchangeable, not an ODB benefit (2) · strengths: 20mcg & 100mcg, 0.03mg & 0.15mg, 3 Phase · Tab-21 Pk, Tab-28 Pk, Tab-91 Pk
· 6 products · General benefit · strengths: 0.035mg & 0.5mg, 0.035mg & 1mg, 3 Phase · Tab-21 Pk, Tab-28 Pk
· 4 products · General benefit · strengths: 0.02mg & 1mg, 0.03mg & 1.5mg · Tab-21 Pk, Tab-28 Pk
· 10 products · Listed, not a benefit (4), General benefit (6) · strengths: 3 Phase · Tab-21 Pk, Tab-28 Pk
· 1 products · General benefit · strengths: 4mg · Tab-28 Tab Pk
· 4 products · General benefit · strengths: 1.5mg · Tab-1 Tab Pk
· 10 products · Temporary benefit (2), General benefit; DIN status E (meaning unconfirmed); confirm discontinuation/availability with Health Canada (3), General benefit (4), Listed, not a benefit (1) · strengths: 150mg/mL, 2.5mg, 5mg, 10mg, 100mg · Inj Sol-1mL Pref Syr, Tab
· 3 products · Listed, not a benefit (1), General benefit (2) · strengths: 0.35mg · Tab-28 Pk
· 5 products ·
Limited Use, codes 432 · strengths: 2mg · Tab
· 6 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 2mg & 0.035mg · Tab-21 Pk
· 8 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 100mg · Cap
Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=2026-09-22; class 68:32
Full class listing
Related classes: 68:04 Corticosteroids, 68:08 Androgens, 68:12 Contraceptives, 68:16 Estrogens, 68:20 Anti-Diabetic Agents, 68:24 Parathyroid Agents, 68:28 Pituitary Agents, 68:36 Thyroids, 68:38 Anti-Thyroids
Same formulary class, not same indication: class membership alone does not establish equivalent uses.